EMSY

EMSY is a nuclear chromatin regulatory protein that functions as a transcriptional repressor and modulator of homologous recombination repair by bridging interactions between chromatin-modifying complexes and gene-specific promoters. Through its N-terminal ENT domain, EMSY homodimerizes and binds HP1beta via a non-canonical chromoshadow domain interaction, while forming complexes with KDM5A/SIN3B at H3K4me3-marked promoters and recruiting KDM5B to specific loci such as the miR-31 promoter via ETS-1, thereby reshaping H3K4 methylation and gene expression (PMID:15947784, PMID:26841866, PMID:24582497, PMID:38290515). EMSY directly binds the BRCA2 exon 3-encoded region, silencing its transactivation potential, and when overexpressed or stabilized—as occurs upon loss of KEAP1-mediated ubiquitin-proteasomal degradation—impairs BRCA2/RAD51/PALB2-dependent homologous recombination repair, producing a BRCAness phenotype and suppressing STING-mediated innate immune signaling (PMID:14651845, PMID:21409565, PMID:34963055). EMSY is post-translationally regulated by Akt1 phosphorylation at Ser209, which relieves its repression of interferon-stimulated genes, and by PKA phosphorylation at Thr207, which is required for its suppression of DNA damage repair through a BRCA2-independent mechanism (PMID:22315412, PMID:28099152).

1. 2003 High

   The discovery of EMSY as a direct BRCA2-binding partner that silences the BRCA2 exon 3 activation domain and localizes to DNA damage sites established it as a candidate link between chromatin regulation and homologous recombination repair.

   Evidence Protein-protein binding assays, transactivation reporter, co-IP with HP1beta/BS69, immunofluorescence after DNA damage in human cells

   PMID:14651845

   Open questions at the time

   • Mechanism by which EMSY silences BRCA2 transcriptional activity was not defined
   • Whether EMSY directly impairs HR repair was untested
   • Nature of EMSY chromatin targeting unknown
2. 2005 High

   Structural determination of the ENT domain and its HP1beta complex revealed that EMSY homodimerizes through its helical bundle and engages HP1 chromoshadow domains via a non-canonical motif, providing a molecular framework for its chromatin association.

   Evidence Crystal structures at 2.0 Å (ENT domain) and 1.8 Å (HP1beta–EMSY complex), NMR, biophysical binding assays

   PMID:15947784 PMID:15978617 PMID:16615912

   Open questions at the time

   • Whether HP1beta interaction is required for EMSY's repressive or DNA repair functions was not tested
   • Full-length EMSY structure remains undetermined
3. 2005 Medium

   Overexpression of the BRCA2-interacting fragment of EMSY was shown to induce progressive chromosomal instability in mammary epithelial cells, providing the first functional evidence that EMSY excess phenocopies BRCA2 loss.

   Evidence Lentiviral transduction of truncated EMSY in human mammary epithelial cells, metaphase chromosome analysis with and without mitomycin C

   PMID:16145051

   Open questions at the time

   • Used truncated rather than full-length EMSY
   • Direct measurement of HR pathway was not performed
   • In vivo relevance of overexpression levels not established
4. 2011 Medium

   Functional HR repair assays demonstrated that EMSY overexpression directly represses BRCA2/RAD51-mediated homologous recombination by competing with PALB2 and RPA for the BRCA2 N-terminus, distinguishing its repair-suppressive role from transcriptional effects.

   Evidence DR-GFP recombination assay, epistasis analysis with PALB2 and RPA in human cells

   PMID:21409565

   Open questions at the time

   • Single laboratory study
   • Endogenous EMSY stoichiometry effects not examined
   • Structural basis of EMSY–PALB2 competition unknown
5. 2012 High

   Identification of Akt1-mediated phosphorylation of EMSY at Ser209 and demonstration of EMSY as a direct transcriptional repressor at ISG promoters established a signaling axis linking PI3K/Akt to innate immune gene regulation via EMSY.

   Evidence In vitro kinase assay, ChIP at ISG promoters, siRNA knockdown, overexpression reporters, viral infection model

   PMID:22315412

   Open questions at the time

   • Whether Ser209 phosphorylation alters EMSY–BRCA2 interaction was not addressed
   • Phosphatase reversing the modification unknown
   • In vivo immune consequences not tested
6. 2014 High

   EMSY was shown to repress miR-31 transcription by being recruited to its promoter via ETS-1 and delivering the H3K4me3 demethylase KDM5B, revealing a gene-specific mechanism linking EMSY to epigenetic silencing and metastatic transformation.

   Evidence ChIP, co-IP, luciferase reporter, in vitro transformation assay, in vivo tumor/metastasis models with miR-31 rescue

   PMID:24582497

   Open questions at the time

   • How many other loci use the ETS-1/EMSY/KDM5B axis was unknown
   • Whether KDM5B recruitment is the sole effector of miR-31 repression not tested
7. 2016 High

   Quantitative proteomics and ChIP-seq revealed that EMSY forms a stable complex with KDM5A/SIN3B at H3K4me3-marked active promoters, recruited by ZNF131, broadening its role from a gene-specific repressor to a genome-wide chromatin regulator.

   Evidence Quantitative interaction proteomics (mass spectrometry), ChIP-seq, EMSY knockout and rescue in human cells

   PMID:26841866

   Open questions at the time

   • Whether KDM5A and KDM5B operate at overlapping or distinct EMSY target loci was not resolved
   • Whether SIN3B is required for EMSY's repressive activity was not demonstrated
8. 2017 Medium

   Discovery that PKA phosphorylates EMSY at Thr207 and that this modification is required for EMSY-driven DNA damage repair suppression through a BRCA2-independent mechanism identified a second kinase input and an alternative pathway for EMSY's repair-inhibitory function.

   Evidence In vitro kinase assay, DR-GFP assay, RAD51 foci assay, site-directed mutagenesis

   PMID:28099152

   Open questions at the time

   • BRCA2-independent mechanism downstream of pThr207 not identified
   • Single laboratory
   • Relationship between Akt1 (Ser209) and PKA (Thr207) phosphorylation events not examined
9. 2021 High

   Identification of KEAP1 as the E3 ligase adaptor targeting EMSY for proteasomal degradation unified the BRCAness and innate immune evasion phenotypes: KEAP1 loss stabilizes EMSY, which impairs HR repair and suppresses STING signaling, explaining PARP inhibitor sensitivity in KEAP1-mutant NSCLC.

   Evidence Ubiquitination assays, HR repair assays, PARP inhibitor sensitivity, STING agonist treatment, in vivo tumor models in NSCLC

   PMID:34963055

   Open questions at the time

   • Degron motif on EMSY for KEAP1 recognition not mapped
   • Whether other E3 ligases also regulate EMSY is unknown
   • Applicability beyond NSCLC not established
10. 2024 Medium

    EMSY was found to competitively bind the JmjC catalytic domain of KDM5B and directly inhibit its demethylase activity, linking EMSY to H3K4me3 preservation at metabolic loci and cancer stem cell self-renewal.

    Evidence Co-IP, KDM5B enzyme activity assay, H3K4 methylation and metabolomics analysis, ALDH+ cell enrichment

    PMID:38290515

    Open questions at the time

    • Whether EMSY inhibition of KDM5B enzymatic activity operates at the same loci as EMSY-mediated KDM5B recruitment (miR-31) is unresolved
    • Single laboratory
    • Structural basis of JmjC domain inhibition by EMSY unknown

• Major unresolved questions include the full-length structure of EMSY, how its multiple phosphorylation events and KEAP1-mediated degradation are coordinated in vivo, and whether the opposing modes of KDM5B regulation (recruitment vs. enzymatic inhibition) are context-dependent.
• No full-length EMSY structure
• Integrated model of Akt1/PKA phosphorylation and KEAP1 degradation regulation absent
• Context rules for KDM5B recruitment vs. inhibition undefined
• Genome-wide target repertoire under physiological EMSY levels not mapped